Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.82B -14.8%
Revenue (ttm)	242.70M +22.5%
Net Income	-25.20M
EPS	-1.53
Shares Out	16.65M
PE Ratio	n/a
Forward PE	61.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,792
Average Volume	17,334
Open	108.80
Previous Close	109.00
Day's Range	106.00 - 108.80
52-Week Range	83.30 - 159.60
Beta	0.68
RSI	54.36
Earnings Date	Feb 12, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 108
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.